| Literature DB >> 20519656 |
Mohammad Afkhami-Ardekani1, Saleh Zahedi-Asl, Maryam Rashidi, Mitra Atifah, Farhad Hosseinpanah, Fereidoun Azizi.
Abstract
OBJECTIVE: To assess the incidence and trend of the metabolic syndrome phenotype in adolescents from the Tehran Lipid and Glucose Study during 3.6 years of follow-up. RESEARCH DESIGN AND METHODS: A total of 932 adolescents, aged 10-19 years, who had complete data and returned for reassessment 3.6 years later were investigated.Entities:
Mesh:
Year: 2010 PMID: 20519656 PMCID: PMC2928373 DOI: 10.2337/dc09-0023
Source DB: PubMed Journal: Diabetes Care ISSN: 0149-5992 Impact factor: 17.152
Baseline and follow-up prevalence, incidence, and instability of metabolic syndrome in adolescents: the TLGS
| Definition | Prevalence (95% CI) (baseline) | Instability (95% CI) | Incidence (95% CI) | Follow-up prevalence (95% CI) | ||||
|---|---|---|---|---|---|---|---|---|
| Total | Baseline overweight | Total | Baseline overweight | Total | Baseline overweight | Total | Baseline overweight | |
| Pediatric AHA | 4.1 (2.8–5) | 34.2 (19–49) | 2.6 (1.5–3) | 15.8 (4–27) | 8.3 (6–10) | 48 (53–96) | 9.4 (7–11) | 50 (34–65) |
| Pediatric ATP III | 7.4 (5.7–9) | 57.9 (42–73) | 5.6 (4–7) | 36.8 (21–52) | 5.2 (3–6) | 44 (19–68) | 6.7 (5–8) | 32 (16–46) |
| Pediatric NHANES III | 13.6 (11–15) | 63.2 (47–78) | 7.8 (6–9) | 31.6 (16–46) | 8.8 (6–10) | 50 (19–68) | 13.4 (11–15) | 50 (34–65) |
| Pediatric IDF | 3.5 (2.3–4.7) | 34.2 (19–49) | 2 (1–2) | 21.1 (8–34) | 6.8 (5–8) | 36 (31–80) | 8 (6–9) | 37 (21–52) |
*Instability was defined as the percentage of baseline metabolic syndrome–positive adolescents who were metabolic syndrome–negative at follow-up.
†Incidence was defined as the proportion of new cases from those adolescents who had been metabolic syndrome–negative at baseline.